Sigyn Therapeutics Files 8-K on Material Agreement; Details Undisclosed
Ticker: SIGY · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action, undisclosed-terms
TL;DR
**Sigyn Therapeutics signed a big deal, but they're not telling us what it is yet.**
AI Summary
Sigyn Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on January 9, 2024. While the filing indicates a significant agreement, it does not disclose the specific details of the agreement or the parties involved. This lack of transparency means investors are left in the dark about a potentially crucial development, making it difficult to assess the company's future prospects or the impact on its stock price.
Why It Matters
Investors need to know the specifics of any material definitive agreement to understand its potential impact on the company's financial health and future growth. Without these details, it's impossible to properly evaluate the stock.
Risk Assessment
Risk Level: medium — The filing indicates a material event but provides no details, creating uncertainty and making it difficult for investors to assess the company's situation.
Analyst Insight
A smart investor would hold off on making any significant decisions regarding Sigyn Therapeutics stock until more specific details about the 'Material Definitive Agreement' are disclosed, as the current filing lacks critical information for evaluation.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 9, 2024 (date) — date of the earliest event reported
- January 11, 2024 (date) — date the 8-K was filed
Forward-Looking Statements
- Sigyn Therapeutics will file an amendment or a subsequent 8-K providing more details about the material definitive agreement. (Sigyn Therapeutics, Inc.) — medium confidence, target: 2024-02-11
FAQ
What specific type of material definitive agreement did Sigyn Therapeutics, Inc. enter into?
The filing states 'Entry into a Material Definitive Agreement' but does not specify the type of agreement (e.g., merger, acquisition, debt financing, partnership).
Who are the parties involved in the material definitive agreement reported by Sigyn Therapeutics, Inc.?
The 8-K filing does not disclose the names of any other parties involved in the material definitive agreement.
What are the key terms or financial implications of the material definitive agreement?
The filing provides no details regarding the key terms, financial implications, or any other specific provisions of the agreement.
Why did Sigyn Therapeutics, Inc. not provide more details about the material definitive agreement in this 8-K filing?
The filing itself does not explain why specific details about the agreement were omitted. It only states that such an event occurred on January 9, 2024.
What is the business address and phone number of Sigyn Therapeutics, Inc. as listed in the filing?
The business address is 2468 Historic Decatur Road, Suite 140, San Diego, California 92106, and the telephone number is 619.368.2000.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-11 15:25:29
Key Financial Figures
- $0 — 4,000 shares of common stock, par value $0.001, shall be surrendered by the Shareh
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 2KB
- ex10-1_001.jpg (GRAPHIC) — 342KB
- ex10-1_002.jpg (GRAPHIC) — 57KB
- 0001493152-24-002048.txt ( ) — 757KB
- sigy-20240109.xsd (EX-101.SCH) — 3KB
- sigy-20240109_lab.xml (EX-101.LAB) — 33KB
- sigy-20240109_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events As a result of the Share Surrender Agreement described in Item 1.01, and the conversion of various convertible notes since the date of the Company's most recent Quarterly Report on Form 10-Q, the Company is reporting that as of the date hereof, it has 48,972,602 shares of common stock outstanding. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Share Surrender Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: January 11, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO